1. Antibody-drug Conjugate/ADC Related
  2. Antibody-Drug Conjugates (ADCs)
  3. Farletuzumab ecteribulin

Farletuzumab ecteribulin  (Synonyms: MORAb-202)

目录号: HY-P99612 纯度: 97.87%

Farletuzumab ecteribulin (MORAb-202) 是一种抗体-活性分子偶联物 (ADC),由人源化抗人叶酸受体 α (FRA) 抗体 Farletuzumab (HY-P99153) 通过还原的链间二硫键与 Mal-PEG2-Val-Cit-PAB-eribulin 偶联而成。Farletuzumab ecteribulin 的活性分子抗体比为 4.0。Farletuzumab ecteribulin 在体外对 FRA 阳性细胞具有高度细胞毒性。Farletuzumab ecteribulin 具有有效的抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Farletuzumab ecteribulin Chemical Structure

Farletuzumab ecteribulin Chemical Structure

CAS No. : 2407465-18-1

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内


3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥12000
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products
  • 生物活性

  • 纯度 & 产品资料

  • 参考文献


Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

(In Vitro)

Farletuzumab ecteribulin (MORAb-202; 5.1 pM-10 μM; 5 天) 在体外对 FRA 阳性细胞具有高度细胞毒性 (IGROV-1: IC50=1 nM, NCI-H2110: IC50=74 nM, A431-A3: IC50=2.3 μM)[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line: Human IGROV-1, OVCAR3-A1, NCI-H2110, A431-A3, and SJSA-1 cells
Concentration: 5.1 pM-10 μM
Incubation Time: 5 days
Result: MORAb-202 showed potent cytotoxicity against IGROV-1 (IC50=1 nM), NCI-H2110 (IC50=74 nM), and A431-A3 (IC50=2.3 μM).
Exhibited little killing activity against the FRA-negative cell line SJSA-1 (IC50>10 μM).
(In Vivo)

Farletuzumab ecteribulin (MORAb-202; 静脉给药; 第 0 天单次注射 1, 5 mg/kg; 或每 11 天注射一次 5 mg/kg, 共2次; 60 天) 在一次或两次 5 mg/kg 剂量下具有显着的抗肿瘤活性[1]
Farletuzumab ecteribulin (2mg/kg; 静脉给药) 第 1 天在雄性和雌性食蟹猴中的 T1/2 分别为 192 和 162 小时,AUC(0-t) 分别为 7160 和 6300 ug·h/mL[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SWISS nude mice with triple-negative breast cancer (TNBC) patient-derived xenograft (PDx) model (OD-BRE-0631)[1].
Dosage: 1, 5 mg/kg
Administration: IV; single injection 1, 5 mg/kg at day 0 ((Q1Dx1) or 5 mg/kg every 11 days (Q11Dx2)); 60 days
Result: A significant antitumor activity was observed in mice treated once or twice 5 mg/kg, while no antitumor activity compared with vehicle group was observed in mice treated with 1 mg/kg.
Animal Model: Male and female cynomolgus monkeys[1].
Dosage: 2mg/kg (Pharmacokinetic Analysis)
Administration: IV
Result: Had a T1/2s of 192 and 162 hours and AUC(0-t)s of 7160 and 6300 ug·h/mL for male and female cynomolgus monkeys on Day 1.
Clinical Trial



Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.


Your information is safe with us. * Required Fields.



* 需求量:

* 客户姓名:


* Email:

* 电话:


* 公司或机构名称:


Bulk Inquiry

Inquiry Information

Farletuzumab ecteribulin